Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02161185 · ClinicalTrials.gov registry record · Phase 3
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
A Phase 3 study, sponsored by UCB Biopharma S.P.R.L..
- Terminated
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT02161185: Clinical Trial Phase 3 study, sponsored by UCB Biopharma S.P.R.L..
NCT02161185 is a Phase 3 study that was terminated before completion, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 7 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02161185, a Phase 3 study, was terminated before completion, sponsored by UCB Biopharma S.P.R.L..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
Primary Outcome
Number of Participants with Death, Serious Adverse Events, Treatment emergent adverse events (TEAEs) leading to subject discontinuation from study
Interventions
- DRUG USL261
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Why NCT02161185 stopped before completion
NCT02161185 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which USL261 is the first listed.
NCT02161185 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02161185 about?
NCT02161185 is a clinical study titled "A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters". The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
What is the current status of trial NCT02161185?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2014-05. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02161185?
The interventions under investigation include: USL261 (DRUG).
Who is sponsoring clinical trial NCT02161185?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02161185's enrollment target sits among peer trials
7 1995th of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia